NO20073404L - Kaliumsalt av en HIV-integraseinhibitor - Google Patents

Kaliumsalt av en HIV-integraseinhibitor

Info

Publication number
NO20073404L
NO20073404L NO20073404A NO20073404A NO20073404L NO 20073404 L NO20073404 L NO 20073404L NO 20073404 A NO20073404 A NO 20073404A NO 20073404 A NO20073404 A NO 20073404A NO 20073404 L NO20073404 L NO 20073404L
Authority
NO
Norway
Prior art keywords
integrase inhibitor
hiv integrase
potassium salt
compound
treating
Prior art date
Application number
NO20073404A
Other languages
English (en)
Other versions
NO338784B1 (no
Inventor
Henry G Morrison
Kevin M Belyk
Philip Jones
Vincenzo Summa
Original Assignee
Angeletti P Ist Richerche Bio
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36171569&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20073404(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Angeletti P Ist Richerche Bio filed Critical Angeletti P Ist Richerche Bio
Publication of NO20073404L publication Critical patent/NO20073404L/no
Publication of NO338784B1 publication Critical patent/NO338784B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • C07D239/545—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/557—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms, e.g. orotic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D313/00—Heterocyclic compounds containing rings of more than six members having one oxygen atom as the only ring hetero atom
    • C07D313/02—Seven-membered rings
    • C07D313/06—Seven-membered rings condensed with carbocyclic rings or ring systems
    • C07D313/10—Seven-membered rings condensed with carbocyclic rings or ring systems condensed with two six-membered rings
    • C07D313/12—[b,e]-condensed

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Kaliumsalter av forbindelse A beskrives, hvori forbindelse A har formelen (I): Forbindelse A er en HIV-integraseinhibitor som er anvendbar for behandling eller forebyggelse av HIV-infeksjon, for forsinkelse av begynnelsen av AIDS og for behandling eller forebyggelse av AIDS.
NO20073404A 2004-12-03 2007-07-02 Vannfritt krystallinsk monokaliumsalt av en HIV-integraseinhibitor, farmasøytisk preparat derav, dets anvendelse i terapi, og dets anvendelse ved fremstilling av et medikament for behandling eller forebyggelse av HIV-infeksjon, eller for behandling, forebyggelse eller forsinkelse av begynnelsen av AIDS. NO338784B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US63313204P 2004-12-03 2004-12-03
PCT/US2005/043728 WO2006060712A2 (en) 2004-12-03 2005-12-02 Potassium salt of an hiv integrase inhibitor

Publications (2)

Publication Number Publication Date
NO20073404L true NO20073404L (no) 2007-07-02
NO338784B1 NO338784B1 (no) 2016-10-17

Family

ID=36171569

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20073404A NO338784B1 (no) 2004-12-03 2007-07-02 Vannfritt krystallinsk monokaliumsalt av en HIV-integraseinhibitor, farmasøytisk preparat derav, dets anvendelse i terapi, og dets anvendelse ved fremstilling av et medikament for behandling eller forebyggelse av HIV-infeksjon, eller for behandling, forebyggelse eller forsinkelse av begynnelsen av AIDS.

Country Status (36)

Country Link
US (2) US7754731B2 (no)
EP (2) EP1819700B1 (no)
JP (1) JP4705956B2 (no)
KR (2) KR20130122031A (no)
CN (1) CN101068793B (no)
AR (2) AR052034A1 (no)
AT (2) ATE534645T1 (no)
AU (1) AU2005311671B8 (no)
BR (1) BRPI0518760A8 (no)
CA (1) CA2588398C (no)
CR (1) CR9146A (no)
CY (1) CY1112859T1 (no)
DK (1) DK1819700T3 (no)
EA (1) EA012418B1 (no)
ES (2) ES2370136T3 (no)
GE (1) GEP20105086B (no)
HK (1) HK1115011A1 (no)
HR (1) HRP20120066T1 (no)
IL (1) IL183614A (no)
MA (1) MA29120B1 (no)
ME (1) ME01985B (no)
MX (1) MX2007006639A (no)
MY (1) MY144320A (no)
NI (1) NI200700138A (no)
NO (1) NO338784B1 (no)
NZ (1) NZ555376A (no)
PE (1) PE20061148A1 (no)
PL (1) PL1819700T3 (no)
PT (1) PT1819700E (no)
RS (1) RS52197B (no)
SI (1) SI1819700T1 (no)
TN (1) TNSN07215A1 (no)
TW (1) TWI344463B (no)
UA (1) UA87884C2 (no)
WO (2) WO2006060712A2 (no)
ZA (1) ZA200704130B (no)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL1725528T3 (pl) 2004-03-11 2013-12-31 4Sc Ag Sulfonylopirole jako inhibitory HDAC
NZ555215A (en) * 2004-12-03 2010-08-27 Merck Sharp & Dohme Use of atazanavir for improving the pharmacokinetics of raltegravir
AU2005311714B2 (en) * 2004-12-03 2010-09-30 Merck Sharp & Dohme Corp. Pharmaceutical composition containing an anti-nucleating agent
AU2005311652B2 (en) * 2004-12-03 2010-12-02 Merck Sharp & Dohme Corp. Pharmaceutical formulation of carboxamide HIV integrase inhibitors containing a release rate controlling composition
JP5197564B2 (ja) * 2006-03-14 2013-05-15 メルク・シャープ・エンド・ドーム・コーポレイション 微細粉砕及び微細な種での結晶化により有機結晶微細粒子組成物を製造する方法
US7888375B2 (en) 2006-07-19 2011-02-15 The University Of Georgia Research Foundation, Inc Pyridinone diketo acids: inhibitors of HIV replication
WO2009009531A2 (en) * 2007-07-09 2009-01-15 Concert Pharmaceuticals Inc. Pyrimidinecarboxamide derivatives for the treatment of hiv infections
US8686141B2 (en) 2008-01-08 2014-04-01 Merck Sharp & Dohme Corp. Process for preparing N-substituted hydroxypyrimidinone carboxamides
ES2549387T3 (es) * 2009-06-02 2015-10-27 Hetero Research Foundation Procedimiento de preparación de raltegravir potásico amorfo
WO2011024192A2 (en) 2009-07-27 2011-03-03 Matrix Laboratories Ltd Novel polymorphs of raltegravir
RS62600B1 (sr) 2009-10-26 2021-12-31 Merck Sharp & Dohme Čvrste farmaceutske kompozicije koje sadrže inhibitor integraze
DE102009056636A1 (de) 2009-12-02 2011-06-09 Ratiopharm Gmbh Raltegravir-Polymorphe
EP2509949B1 (en) * 2009-12-07 2014-04-23 University Of Georgia Research Foundation, Inc. Pyridinone hydroxycyclopentyl carboxamides: hiv integrase inhibitors with therapeutic applications
ES2362598B1 (es) * 2009-12-17 2012-06-13 Consejo Superior De Investigaciones Científicas (Csic) Uso del raltegravir y derivados para la elaboración de medicamentos destinados al tratamiento de infecciones por herpesvirus.
EP2552915B1 (en) * 2010-04-01 2017-07-19 Critical Outcome Technologies Inc. Compounds for the treatment of hiv
US20130079360A1 (en) * 2010-04-01 2013-03-28 Ana KWOKAL Raltegravir salts and crystalline forms thereof
WO2011148381A1 (en) * 2010-05-25 2011-12-01 Hetero Research Foundation Salts of raltegravir
US9107922B2 (en) 2010-07-16 2015-08-18 Concert Pharmaceuticals, Inc. Pyrimidinecarboxamide derivatives
CN101914067B (zh) * 2010-08-26 2012-07-11 陈岱岭 N-甲基嘧啶酮的合成方法
JO3209B1 (ar) * 2010-11-05 2018-03-08 H Lundbeck As طريقة لتصنيع نالتريكسون
WO2012103105A1 (en) 2011-01-24 2012-08-02 Assia Chemical Industries Ltd. Processes for preparing raltegravir and intermediates in the processes
WO2012106534A2 (en) * 2011-02-02 2012-08-09 The Regents Of The University Of California Hiv integrase inhibitors
WO2012137142A1 (en) 2011-04-06 2012-10-11 Lupin Limited Novel salts of raltegravir
WO2012145446A1 (en) * 2011-04-22 2012-10-26 Merck Sharp & Dohme Corp. Taste-masked formulations of raltegravir
US9968607B2 (en) 2011-04-25 2018-05-15 Hetero Research Foundation Pharmaceutical compositions of raltegravir, methods of preparation and methods of use therof
EP2522665A1 (en) 2011-05-03 2012-11-14 Sandoz Ag Crystalline sodium salt of an HIV integrase inhibitor
ES2450944T3 (es) 2011-06-01 2014-03-25 Ratiopharm Gmbh Composición y comprimido que comprenden raltegravir
WO2013037731A1 (de) 2011-09-16 2013-03-21 Hexal Ag Neue polymorphe form von raltegravir-kalium
CN103130787B (zh) * 2011-11-24 2015-06-10 南开大学 嘧啶酮酰胺类化合物及其制备方法、抗hiv活性和抗tmv活性
CN103130788B (zh) * 2011-11-24 2015-09-02 南开大学 嘧啶酰胺类化合物及其制备方法、抗hiv活性和抗tmv活性
ES2825029T3 (es) 2011-12-26 2021-05-14 Emcure Pharmaceuticals Ltd Síntesis de raltegravir
CA2863575A1 (en) 2012-01-25 2013-08-01 Lupin Limited Stable amorphous raltegravir potassium premix and process for the preparation thereof
WO2014064711A2 (en) * 2012-10-22 2014-05-01 Hetero Research Foundation Methods of administering raltegravir and raltegravir compositions
EP2818470A1 (en) 2013-06-27 2014-12-31 Basf Se Cocrystals of raltegravir potassium
EP3022209B1 (en) 2013-07-17 2018-03-07 ratiopharm GmbH Dolutegravir potassium salt
PT3102565T (pt) 2014-02-03 2019-04-01 Mylan Laboratories Ltd Processos para a preparação de intermediários de raltegravir
US10391178B2 (en) 2014-03-21 2019-08-27 Mylan Laboratories Limited Premix of crystalline raltegravir potassium salt and a process for the preparation thereof
US10257840B2 (en) 2014-10-22 2019-04-09 Telefonaktiebolaget Lm Ericsson (Publ) Operation of wireless local area network in the presence of periodic interference
WO2016075605A1 (en) 2014-11-10 2016-05-19 Aurobindo Pharma Ltd An improved process for the preparation of raltegravir
WO2017220208A1 (en) 2016-06-21 2017-12-28 Pharmathen S.A. Process for preparing compounds useful as intermediates for the preparation of raltegravir
EP3512854A1 (en) 2016-09-15 2019-07-24 Lupin Limited Process for the preparation of pure and stable crystalline raltegravir potassium form 3
CN108610338A (zh) * 2016-12-12 2018-10-02 天津国际生物医药联合研究院 一种嘧啶酮酰胺类化合物的制备方法
EP3710445B1 (en) 2017-11-14 2022-03-16 Cambrex Profarmaco Milano S.r.l. Process for the preparation of raltegravir
US20210290548A1 (en) * 2018-06-06 2021-09-23 Merck Sharp & Dohme Corp. Formulations of raltegravir
GB201907305D0 (en) * 2019-05-23 2019-07-10 Douglas Pharmaceuticals Ltd Treatment of conditions
US20230073216A1 (en) 2020-01-23 2023-03-09 Lupin Limited Pharmaceutical Compositions of Raltegravir

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH624391A5 (no) * 1976-12-14 1981-07-31 Ciba Geigy Ag
US5413999A (en) 1991-11-08 1995-05-09 Merck & Co., Inc. HIV protease inhibitors useful for the treatment of AIDS
US5717097A (en) 1991-11-08 1998-02-10 Merck & Co., Inc. HIV protease inhibitors useful for the treatment of AIDS
IL121789A (en) * 1996-10-03 2001-06-14 Rohm & Haas A medicinal product for inhibiting mammalian cell tumors
AP2001002169A0 (en) 1998-12-25 2001-06-30 Shionogi & Co Aromatic heterocycle compounds having hiv intergrase inhibiting activities
IT1318424B1 (it) 2000-03-24 2003-08-25 Unihart Corp Composti con attivita' anti-hiv.
IL155089A0 (en) 2000-10-12 2003-10-31 Merck & Co Inc Aza and polyaza-naphthalenyl carboxamides useful as hiv integrase inhibitors
GB0028483D0 (en) 2000-11-22 2001-01-10 Hoffmann La Roche Hydroxyethylamine HIV protease inhibitors
EA007060B1 (ru) 2001-10-26 2006-06-30 Иституто Ди Ричерке Ди Биолоджиа Молеколаре П. Анджелетти Спа N-замещённые гидроксипиримидинон-карбоксамидные ингибиторы вич интегразы
US7354932B2 (en) 2001-12-21 2008-04-08 Anormed, Inc. Chemokine receptor binding heterocyclic compounds with enhanced efficacy
MXPA04006136A (es) 2001-12-21 2004-11-01 Anormed Inc Compuestos heterociclicos que se unen a receptor de quimiocina con eficacia incrementada.
SK2662004A3 (sk) 2002-11-20 2005-06-02 Japan Tobacco, Inc. Zlúčenina s obsahom 4-oxochinolínu a jej použitie ako inhibítora integráz
BR0317749A (pt) 2002-12-27 2005-11-22 Angeletti P Ist Richerche Bio Composto, composição farmacêutica, e, uso de um composto
TW200423930A (en) 2003-02-18 2004-11-16 Hoffmann La Roche Non-nucleoside reverse transcriptase inhibitors
AU2005311652B2 (en) 2004-12-03 2010-12-02 Merck Sharp & Dohme Corp. Pharmaceutical formulation of carboxamide HIV integrase inhibitors containing a release rate controlling composition
NZ555215A (en) 2004-12-03 2010-08-27 Merck Sharp & Dohme Use of atazanavir for improving the pharmacokinetics of raltegravir
AU2005311714B2 (en) 2004-12-03 2010-09-30 Merck Sharp & Dohme Corp. Pharmaceutical composition containing an anti-nucleating agent

Also Published As

Publication number Publication date
EP1819683B1 (en) 2011-08-03
CY1112859T1 (el) 2016-04-13
HRP20120066T1 (hr) 2012-03-31
JP4705956B2 (ja) 2011-06-22
EA200701204A1 (ru) 2007-12-28
NZ555376A (en) 2009-11-27
GEP20105086B (en) 2010-10-11
US20100249410A1 (en) 2010-09-30
IL183614A0 (en) 2007-09-20
AU2005311671A1 (en) 2006-06-08
AU2005311671B2 (en) 2011-01-27
JP2008521933A (ja) 2008-06-26
KR20130122031A (ko) 2013-11-06
RS52197B (en) 2012-10-31
BRPI0518760A8 (pt) 2017-12-12
CA2588398A1 (en) 2006-06-08
UA87884C2 (uk) 2009-08-25
US8357798B2 (en) 2013-01-22
TNSN07215A1 (en) 2008-11-21
CR9146A (es) 2007-10-04
EP1819700B1 (en) 2011-11-23
KR20070089990A (ko) 2007-09-04
MX2007006639A (es) 2007-06-19
US20060122205A1 (en) 2006-06-08
WO2006060730A2 (en) 2006-06-08
ATE518844T1 (de) 2011-08-15
BRPI0518760A2 (pt) 2008-12-09
CA2588398C (en) 2011-07-12
ZA200704130B (en) 2008-08-27
ES2370136T3 (es) 2011-12-13
AR052034A1 (es) 2007-02-28
HK1115011A1 (en) 2008-11-14
ME01985B (me) 2012-10-31
PL1819700T3 (pl) 2012-04-30
DK1819700T3 (da) 2012-03-19
AR101429A2 (es) 2016-12-21
KR101350420B1 (ko) 2014-02-17
NI200700138A (es) 2008-05-13
PT1819700E (pt) 2012-02-01
MY144320A (en) 2011-08-29
WO2006060730A3 (en) 2006-08-17
TW200631944A (en) 2006-09-16
WO2006060712A2 (en) 2006-06-08
CN101068793B (zh) 2011-05-25
SI1819700T1 (sl) 2012-07-31
WO2006060712A3 (en) 2006-09-21
ATE534645T1 (de) 2011-12-15
US7754731B2 (en) 2010-07-13
CN101068793A (zh) 2007-11-07
AU2005311671B8 (en) 2011-02-10
EP1819700A2 (en) 2007-08-22
TWI344463B (en) 2011-07-01
ES2375788T3 (es) 2012-03-06
PE20061148A1 (es) 2006-11-09
NO338784B1 (no) 2016-10-17
IL183614A (en) 2012-03-29
EP1819683A2 (en) 2007-08-22
WO2006060712A9 (en) 2006-07-27
MA29120B1 (fr) 2007-12-03
EA012418B1 (ru) 2009-10-30

Similar Documents

Publication Publication Date Title
NO20073404L (no) Kaliumsalt av en HIV-integraseinhibitor
DK1940786T3 (da) Biphenylderivater og deres anvendelse ved behandling af hepatitis C
EA200601457A1 (ru) Ингибиторы вирусной полимеразы
NO20070368L (no) Virale polymeraseinhibitorer
NO20090405L (no) Ikke-nukleoside revers transcriptase inhibitorer
NO20054195D0 (no) Isoksazolforbindelser som inhibitorer for varmesjokkproteiner
NO20080761L (no) Acykliske Ikur inhibitorer
NO20050346L (no) Nitro-oksyderivater av syklooksygenase-2-inhibitorer
DK1742642T3 (da) Phosphonatanaloge af HIV-integraseinhibitorforbindelser
NO20091553L (no) Fenylderivater og deres anvendelse som immunmodulatorer
NO20081454L (no) Met-kinaseinhibitorer
DE60331187D1 (de) Kinaseinhibitoren
DK1569929T3 (da) Forbindelser og fremgangsmåder til behandling eller forebyggelse af flavi-virusinfektioner
NO20061157L (no) 4-pyramidonderivater og deres anvendelse som peptidylpeptidmeinbibitorer
WO2004004657A3 (en) Hiv integrase inhibitors
EA200801199A1 (ru) Ингибиторы киназы
NO20034661L (no) Nociceptin-analoger
MX2021002199A (es) Inhibidores de sarcomeros cardiacos.
EA201100994A1 (ru) Способ получения производных бисфуранового спирта, соединения, соль, фармацевтическая композиция на ее основе, способ лечения или профилактики ретровирусных инфекций с ее помощью
WO2006014282A3 (en) Prodrugs of hiv protease inhibitors
NO20081888L (no) Triazolforbindelser som lipoksygenaseinhibitorer
TW200716571A (en) Heterocyclic reverse transcriptase inhibitors
NO20070564L (no) Kinoliner uten tiazolinonsubstituenter.
EA200801200A1 (ru) ПРОИЗВОДНЫЕ ПИРАЗОЛИЗОХИНОЛИНМОЧЕВИНЫ В КАЧЕСТВЕ ИНГИБИТОРОВ p38 КИНАЗЫ
DK1970372T3 (da) Salte af 9-oxoacridin-10-eddikesyre med 1-alkylamino-1-deoxy-polyoler

Legal Events

Date Code Title Description
CHAD Change of the owner's name or address (par. 44 patent law, par. patentforskriften)

Owner name: MERCK SHARP & DOHME CORP, IT

CHAD Change of the owner's name or address (par. 44 patent law, par. patentforskriften)

Owner name: MSD ITALIA S.R.L., US